Myriad Genetics price target lowered to $24 from $34 at Scotiabank
The Fly

Myriad Genetics price target lowered to $24 from $34 at Scotiabank

Scotiabank lowered the firm’s price target on Myriad Genetics (MYGN) to $24 from $34 and keeps an Outperform rating on the shares. The firm lowered its estimates for 2025 to reflect the recent medical policy change by UnitedHealth (UNH) to no longer cover PGx panel testing, the analyst tells investors. Scotiabank, however, continues to see significant upside potential if the company continues to deliver on double-digit top line growth, profitability targets, and pipeline progress.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App